| Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy. |
|
Sae Rom Chung, Jin Gu Jeong, Tae Eun Lee, In Cheon You, Min Ahn, Nam Chun Cho |
1Department of Ophthalmology, Jeonbuk National University Medical School, Jeonju, Korea. cnauo@jbnu.ac.kr
2Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Korea.
3Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Korea. |
| 만성 중심장액맥락망막병증에서 경구 스피로놀락톤의 효과 |
|
정새롬1⋅정진구1⋅이태은1,2,3⋅유인천1,2,3⋅안 민1,2,3⋅조남천1,2,3 |
|
전북대학교 의학전문대학원 안과학교실1, 전북대학교 임상의학연구소2, 전북대학교병원 의생명연구원3 |
Correspondence:
Nam Chun Cho,
Email: cnauo@jbnu.ac.kr
|
|
Received: 22 May 2019 • Revised: 11 September 2019 • Accepted: 21 February 2020 |
| Abstract |
PURPOSE
To evaluate the effect of oral spironolactone for non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection. METHODS: Seventeen eyes of 17 patients with non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection from September 2017 to December 2018 were treated with oral spironolactone for 6 months, and changes in central macular thickness, subretinal fluid height, and best-corrected visual acuity (BCVA) were analyzed retrospectively. RESULTS: The central macular thickness decreased from 309.94 ± 105.20 µm at baseline to 259.76 ± 81.83 µm at 3 months, and 243.11 ± 61.98 µm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.016 and p = 0.001, respectively). The subretinal fluid height decreased from 138.05 ± 95.69 µm at baseline to 70.88 ± 83.13 µm at 3 months, and 54.00 ± 56.25 µm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.002 and p = 0.000, respectively). The BCVA (LogMAR) changed from 0.30 ± 0.38 at baseline to 0.35 ± 0.43 at 1 month, 0.29 ± 0.43 at 3 months, and 0.26 ± 0.40 at 6 months. The results at 6 months were statistically significant (Wilcoxon signed-rank test, p = 0.033). There were no side effects in patients treated with oral spironolactone. CONCLUSIONS: In chronic central serous chorioretinopathy, treatment with oral spironolactone significantly reduced the central macular thickness, subretinal fluid height, and the BCVA, without side effects. |
| Key Words:
Bevacizumab;Central serous chorioretinopathy;Spironolactone |
|
PDF Links
Full text via DOI
Download Citation
